Artrya (AYA) Stock Overview
A medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AYA Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Artrya Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.31 |
| 52 Week High | AU$5.24 |
| 52 Week Low | AU$0.56 |
| Beta | 0.51 |
| 1 Month Change | 7.12% |
| 3 Month Change | -29.72% |
| 1 Year Change | 338.41% |
| 3 Year Change | 1,061.40% |
| 5 Year Change | n/a |
| Change since IPO | 117.05% |
Recent News & Updates
Recent updates
US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
Catalysts About Artrya Artrya develops AI-powered cardiac imaging software that helps clinicians assess coronary anatomy, plaque and blood flow from CCTA scans. What are the underlying business or industry changes driving this perspective?We're Hopeful That Artrya (ASX:AYA) Will Use Its Cash Wisely
Aug 22
We Think Artrya (ASX:AYA) Needs To Drive Business Growth Carefully
Nov 28Here's Why We're Not Too Worried About Artrya's (ASX:AYA) Cash Burn Situation
Jul 08We're Not Very Worried About Artrya's (ASX:AYA) Cash Burn Rate
Mar 23Shareholder Returns
| AYA | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 6.1% | 2.7% | 1.4% |
| 1Y | 338.4% | -33.8% | 8.8% |
Return vs Industry: AYA exceeded the Australian Healthcare Services industry which returned -37.4% over the past year.
Return vs Market: AYA exceeded the Australian Market which returned 6.5% over the past year.
Price Volatility
| AYA volatility | |
|---|---|
| AYA Average Weekly Movement | 11.6% |
| Healthcare Services Industry Average Movement | 11.5% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 4.3% |
Stable Share Price: AYA has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AYA's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | John Konstantopoulos | www.artrya.com |
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.
Artrya Limited Fundamentals Summary
| AYA fundamental statistics | |
|---|---|
| Market cap | AU$523.26m |
| Earnings (TTM) | -AU$19.71m |
| Revenue (TTM) | AU$29.00k |
Is AYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYA income statement (TTM) | |
|---|---|
| Revenue | AU$29.00k |
| Cost of Revenue | AU$17.69m |
| Gross Profit | -AU$17.66m |
| Other Expenses | AU$2.05m |
| Earnings | -AU$19.71m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -60,906.90% |
| Net Profit Margin | -67,958.62% |
| Debt/Equity Ratio | 0% |
How did AYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 22:52 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Artrya Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Wilkinson | Venn Brown Pty Ltd |